127 related articles for article (PubMed ID: 17536884)
21. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
22. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
[TBL] [Abstract][Full Text] [Related]
23. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
Schlosser K; Scigalla P
Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
[TBL] [Abstract][Full Text] [Related]
24. Renal safety of ibandronate.
Jackson GH
Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
27. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
Body JJ; Diel IJ; Tripathy D; Bergstrom B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):299-302. PubMed ID: 16882128
[TBL] [Abstract][Full Text] [Related]
28. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
29. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
31. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
Miller PD; Ward P; Pfister T; Leigh C; Body JJ
Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence.
Liberman UA
Drugs Aging; 2006; 23(4):289-98. PubMed ID: 16732688
[TBL] [Abstract][Full Text] [Related]
33. Podocyte Disease Following Treatment with Intravenous Ibandronate in an Older Patient.
Chung YR; Lee HS; Lee DY; Lee SH; Jeong JS; Kim B
Ann Geriatr Med Res; 2024 Jun; 28(2):228-230. PubMed ID: 38383148
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
35. Intravenous pamidronate: infusion rate and safety.
Tyrrell CJ; Collinson M; Madsen EL; Ford JM; Coleman T
Ann Oncol; 1994; 5 Suppl 7():S27-9. PubMed ID: 7873459
[TBL] [Abstract][Full Text] [Related]
36. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
37. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
38. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
39. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study.
Leehey DJ; Palubiak DJ; Chebrolu S; Agarwal R
Nephrol Dial Transplant; 2005 Jan; 20(1):135-40. PubMed ID: 15522899
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
